Haemonetics Balance Sheet Health
Financial Health criteria checks 3/6
Haemonetics has a total shareholder equity of $943.3M and total debt of $871.1M, which brings its debt-to-equity ratio to 92.3%. Its total assets and total liabilities are $2.2B and $1.3B respectively. Haemonetics's EBIT is $199.7M making its interest coverage ratio 22.6. It has cash and short-term investments of $195.1M.
Key information
92.3%
Debt to equity ratio
US$871.06m
Debt
Interest coverage ratio | 22.6x |
Cash | US$195.12m |
Equity | US$943.32m |
Total liabilities | US$1.26b |
Total assets | US$2.20b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: HAZ's short term assets ($765.0M) exceed its short term liabilities ($261.8M).
Long Term Liabilities: HAZ's short term assets ($765.0M) do not cover its long term liabilities ($995.4M).
Debt to Equity History and Analysis
Debt Level: HAZ's net debt to equity ratio (71.7%) is considered high.
Reducing Debt: HAZ's debt to equity ratio has increased from 53.9% to 92.3% over the past 5 years.
Debt Coverage: HAZ's debt is well covered by operating cash flow (22.6%).
Interest Coverage: HAZ's interest payments on its debt are well covered by EBIT (22.6x coverage).